Earnings Call Summary | PaySign(PAYS.US) Q1 2024 Earnings Conference
Earnings Call Summary | PaySign(PAYS.US) Q1 2024 Earnings Conference
The following is a summary of the Paysign, Inc. (PAYS) Q1 2024 Earnings Call Transcript:
以下是Paysign, Inc.（PAYS）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Paysign reported Q1 2024 revenue of $13.2 million, marking a 30% increase year-over-year.
Paysign's adjusted EBITDA increased by 135% to $1.7 million, or $0.03 per fully diluted share, up from $720,000 in the previous year.
Gross dollar load volume and gross spend volume rose by 13% and 11% respectively.
The Patient Affordability business contributed to 59% of the total year-over-year revenue growth with a 305% increase in revenue.
Paysign報告稱，2024年第一季度收入爲1,320萬美元，同比增長30％。
Paysign調整後的息稅折舊攤銷前利潤從去年的72萬美元增長了135％，至170萬美元，攤薄後每股收益爲0.03美元。
美元總負荷量和總支出量分別增長了13％和11％。
患者負擔能力業務貢獻了總收入同比增長的59％，收入增長了305％。
Business Progress:
業務進展：
Paysign expanded its patient affordability programs to reach a total of 53 active programs.
An entrance into retail drug programs with 4 programs added in Q1 and more expected to launch in the future.
The plasma donor compensation business saw an 11% increase in revenue.
The company anticipates adding 15 to 25 new plasma donor centers in 2024.
Paysign is seeking to enter new markets while also investing in its personnel and systems to meet growing demand.
Paysign將其患者負擔能力計劃擴展到總共53個活躍計劃。
零售藥品計劃的入口，第一季度增加了4個項目，預計將來還會推出更多項目。
血漿捐贈者補償業務的收入增長了11％。
該公司預計，2024年將增加15至25個新的血漿捐贈中心。
Paysign正在尋求進入新市場，同時還投資其人員和系統，以滿足不斷增長的需求。
More details: PaySign IR
更多詳情： PaySign IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。